Related Experiment Video
Updated: May 31, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Recent clinical experience with oncolytic viruses
O G Donnelly1, F Errington-Mais, R Prestwich
1Leeds Institute of Molecular Medicine, St James's University Hospital, Beckett Street, Leeds, UK.
Abstract:
There has been interest in using viruses to treat cancer for over a century. Recent clinical efforts, driven on by significant preclinical advances, have focussed on the safety of using replication-competent viruses. Recently published clinical trials of six oncolytic viruses (adenovirus, reovirus, measles, herpes simplex, Newcastle disease virus and vaccinia) have added to the accumulating data that endorse oncolytic viruses as a safe and well tolerated treatment approach. Conclusive evidence of efficacy remains to be demonstrated, but randomised clinical trials are now underway.
Insights
Oncolytic viruses are a century-old concept now showing promise in cancer treatment. Recent trials confirm their safety and tolerability, though efficacy evidence is still pending further clinical studies.
Area of Science:
- Oncology
- Virology
- Immunotherapy
Background:
- The use of viruses to combat cancer has a long history.
- Recent advancements focus on replication-competent oncolytic viruses for cancer therapy.
Purpose of the Study:
- To evaluate the safety and tolerability of oncolytic viruses in clinical settings.
- To assess the potential of oncolytic viruses as a cancer treatment modality.
Main Methods:
- Review of recently published clinical trials involving six types of oncolytic viruses: adenovirus, reovirus, measles, herpes simplex, Newcastle disease virus, and vaccinia.
- Accumulation and analysis of safety and tolerability data from these trials.
Main Results:
- Clinical trials indicate that oncolytic viruses are generally safe and well-tolerated by patients.
- The reviewed oncolytic viruses include adenovirus, reovirus, measles, herpes simplex, Newcastle disease virus, and vaccinia.
Conclusions:
- Oncolytic virus therapy is emerging as a safe and well-tolerated treatment option for cancer.
- Further randomized clinical trials are necessary to establish the definitive efficacy of oncolytic viruses in cancer treatment.
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Mechanisms of Retrovirus-induced Cancers
Mechanisms of Retrovirus-induced Cancers
Subviral Agents
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

